353 related articles for article (PubMed ID: 28409746)
1. The Role of ADAM10 in Alzheimer's Disease.
Yuan XZ; Sun S; Tan CC; Yu JT; Tan L
J Alzheimers Dis; 2017; 58(2):303-322. PubMed ID: 28409746
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein E-mediated Modulation of ADAM10 in Alzheimer's Disease.
Shackleton B; Crawford F; Bachmeier C
Curr Alzheimer Res; 2017; 14(6):578-585. PubMed ID: 28164773
[TBL] [Abstract][Full Text] [Related]
3. ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker.
Manzine PR; Ettcheto M; Cano A; Busquets O; Marcello E; Pelucchi S; Di Luca M; Endres K; Olloquequi J; Camins A; Cominetti MR
Biomed Pharmacother; 2019 May; 113():108661. PubMed ID: 30836275
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding.
Shackleton B; Crawford F; Bachmeier C
Fluids Barriers CNS; 2016 Aug; 13(1):14. PubMed ID: 27503326
[TBL] [Abstract][Full Text] [Related]
5. Activation of peroxisome proliferator-activated receptor α stimulates ADAM10-mediated proteolysis of APP.
Corbett GT; Gonzalez FJ; Pahan K
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8445-50. PubMed ID: 26080426
[TBL] [Abstract][Full Text] [Related]
6. Different Expression Patterns of Amyloid-β Protein Precursor Secretases in Human and Mouse Hippocampal Neurons: A Potential Contribution to Species Differences in Neuronal Susceptibility to Amyloid-β Pathogenesis.
Xu ZQ; Huang H; Chen YL; Gao YY; Xu J; Marshall C; Cai ZY; Xiao M
J Alzheimers Dis; 2016; 51(1):179-95. PubMed ID: 26836155
[TBL] [Abstract][Full Text] [Related]
7. Ube3a deficiency inhibits amyloid plaque formation in APPswe/PS1δE9 mouse model of Alzheimer's disease.
Singh BK; Vatsa N; Kumar V; Shekhar S; Sharma A; Jana NR
Hum Mol Genet; 2017 Oct; 26(20):4042-4054. PubMed ID: 29016862
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic approaches to Alzheimer's disease through stimulating of non-amyloidogenic processing of amyloid precursor protein.
Wang YQ; Qu DH; Wang K
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2389-403. PubMed ID: 27338066
[TBL] [Abstract][Full Text] [Related]
9. Localization and Trafficking of Amyloid-β Protein Precursor and Secretases: Impact on Alzheimer's Disease.
Agostinho P; Pliássova A; Oliveira CR; Cunha RA
J Alzheimers Dis; 2015; 45(2):329-47. PubMed ID: 25589722
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of ADAM10 modulation in Alzheimer's disease: a review of the current evidence.
Khezri MR; Mohebalizadeh M; Ghasemnejad-Berenji M
Cell Commun Signal; 2023 Mar; 21(1):60. PubMed ID: 36918870
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitor apicidin increases expression of the α-secretase ADAM10 through transcription factor USF1-mediated mechanisms.
Hu XT; Zhu BL; Zhao LG; Wang JW; Liu L; Lai YJ; He L; Deng XJ; Chen GJ
FASEB J; 2017 Apr; 31(4):1482-1493. PubMed ID: 28003340
[TBL] [Abstract][Full Text] [Related]
12. Secretases in Alzheimer's disease: Novel insights into proteolysis of APP and TREM2.
Lichtenthaler SF; Tschirner SK; Steiner H
Curr Opin Neurobiol; 2022 Feb; 72():101-110. PubMed ID: 34689040
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of non-amyloidogenic processing of amyloid-β protein precursor by cryptotanshinone involves activation and translocation of ADAM10 and PKC-α.
Durairajan SS; Liu LF; Lu JH; Koo I; Maruyama K; Chung SK; Huang JD; Li M
J Alzheimers Dis; 2011; 25(2):245-62. PubMed ID: 21403388
[TBL] [Abstract][Full Text] [Related]
14. The transmembrane domain of the amyloid precursor protein is required for antiamyloidogenic processing by α-secretase ADAM10.
Hitschler L; Lang T
J Biol Chem; 2022 Jun; 298(6):101911. PubMed ID: 35398353
[TBL] [Abstract][Full Text] [Related]
15. Protein Expression of BACE1 is Downregulated by Donepezil in Alzheimer's Disease Platelets.
Sarno TA; Talib LL; Joaquim HP; Bram JM; Gattaz WF; Forlenza OV
J Alzheimers Dis; 2017; 55(4):1445-1451. PubMed ID: 27858713
[TBL] [Abstract][Full Text] [Related]
16. A Bioengineering Strategy to Control ADAM10 Activity in Living Cells.
Pastore F; Battistoni M; Sollazzo R; Renna P; Paciello F; Li Puma DD; Barone E; Dagliyan O; Ripoli C; Grassi C
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674432
[TBL] [Abstract][Full Text] [Related]
17. Regulatory Effect of Adipose-Derived Mesenchymal Stem Cells and/ or Acitretin on Adam10 Gene in Alzheimer's Disease Rat Model.
Abu Nasra NO; Elzayat EM; Dawood KM; Hagag NM; Yehya MM; Hosney M
Curr Stem Cell Res Ther; 2022; 17(4):370-388. PubMed ID: 35236271
[TBL] [Abstract][Full Text] [Related]
18. Activation of the α-secretase processing of AβPP as a therapeutic approach in Alzheimer's disease.
Vincent B; Govitrapong P
J Alzheimers Dis; 2011; 24 Suppl 2():75-94. PubMed ID: 21422515
[TBL] [Abstract][Full Text] [Related]
19. Identification of disulfiram as a secretase-modulating compound with beneficial effects on Alzheimer's disease hallmarks.
Reinhardt S; Stoye N; Luderer M; Kiefer F; Schmitt U; Lieb K; Endres K
Sci Rep; 2018 Jan; 8(1):1329. PubMed ID: 29358714
[TBL] [Abstract][Full Text] [Related]
20. Effect of a dominant-negative form of ADAM10 in a mouse model of Alzheimer's disease.
Schroeder A; Fahrenholz F; Schmitt U
J Alzheimers Dis; 2009; 16(2):309-14. PubMed ID: 19221420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
